The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Open accessAbstract
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanoma. Therefore, molecular testing for BRAF mutations is a priority in determining the course of therapy. A literature search was performed using MEDLINE/PubMed and scientific congress databases using the terms 'BRAF,' 'mutation,' and 'cancer/tumor.' These results were filtered to include manuscripts that focused on diagnostic tests for determining BRAF mutation status. Numerous BRAF testing methods were identified, including DNA-based companion diagnostic tests and DNA- and protein-based laboratory-developed tests. Herein we review the characteristics of each method and highlight the strengths and weaknesses that should be considered before use and when interpreting results for each patient. Molecular profiling has shown that mutation load increases with melanoma tumor progression and that unique patterns of genetic changes and evolutionary trajectories for different melanoma subtypes can occur. Discordance in the BRAF mutational status between primary and metastatic lesions, as well as intratumoral heterogeneity, is known to occur. Additionally, the development of acquired resistance to combination BRAF and MEK inhibitor therapy is still a formidable obstacle. Therefore, tumor heterogeneity and the development of acquired resistance have important implications for molecular testing and ultimately the treatment of patients with advanced-stage melanoma. Overall, this information may help community oncologists more accurately and effectively interpret results of diagnostic tests within the context of recent data characterizing melanoma tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Coming of age: ten years of next-generation sequencing technologies
Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.49 · Cited by 4,352
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Park, H., Harris, S. M., Boldenow, E., Aronoff, D. M., Rea, M., Xi, C., & Loch‐Caruso, R. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13807 · Cited by 2,087
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Whole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A.-M., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,461
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds229 · Cited by 714
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
High-Resolution DNA Melting Analysis for Simple and Efficient Molecular Diagnostics
Reed, G. H., Kent, J. O., & Wittwer, C. T. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.597 · Cited by 678
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx176 · Cited by 671
Schadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Bastian, B. C. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104658 · Cited by 513
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., & Keilholz, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv297 · Cited by 396
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345
Long, G. V., Wilmott, J. S., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., & Scolyer, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826485c0 · Cited by 298
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 285
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 283
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 271
Resistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., de los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., & Martínez-Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 255
Ihle, M. A., Fassunke, J., König, K., Grünewald, I., Schlaak, M., Kreuzberg, N., Tietze, L., Schildhaus, H.-U., Büttner, R., & Merkelbach-Bruse, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-13 · Cited by 246
Validation of Analytic Methods for Biomarkers Used in Drug Development
Chau, C. H., Rixe, O., McLeod, H., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4535 · Cited by 241
Girotti, M. R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 231
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 217
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 216
Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K., Kefford, R., Hauschild, A., Hwu, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0321 · Cited by 206
Fundamentals of Pyrosequencing
Harrington, C. T., Lin, E. I., Olson, M. T., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0463-ra · Cited by 176
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
de Gramont, A., Watson, S., Ellis, L. M., Rodón, J., Tabernero, J., de Gramont, A., & Hamilton, S. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 176
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Survival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P., McArthur, G. A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 174
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
Detection of BRAF p.V600E Mutations in Melanomas
Colomba, E., Hélias-Rodzewicz, Z., Von Deimling, A., Marin, C., Terrones, N., Pechaud, D., Surel, S., Côté, J.-F., Peschaud, F., Capper, D., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.001 · Cited by 160
Melanoma: a global perspective
Ossio, R., Roldán–Marín, R., Martínez‐Said, H., Adams, D. J., & Robles‐Espinoza, C. D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.43 · Cited by 144
The state of melanoma: challenges and opportunities
Merlino, G. T., Herlyn, M., Fisher, D. E., Bastian, B. C., Flaherty, K. T., Davies, M. A., Wargo, J. A., Curiel‐Lewandrowski, C. N., Weber, M. J., Leachman, S. A., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12475 · Cited by 130
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Xi, L., Pham, T. H.-T., Payabyab, E. C., Sherry, R. M., Rosenberg, S. A., & Raffeld, M. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0613 · Cited by 105
Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
Huang, S. K., & Hoon, D. S. �. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.008 · Cited by 99
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 79
Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., Ladstein, R. G., & Akslen, L. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.44 · Cited by 75
Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma
Yang, G., Rajadurai, A., & Tsao, H. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23931.x · Cited by 73
Schiller, J. H., Pugh, M., Kirkwood, J. M., Karp, D. D., Larson, M., & Borden, E. C. (1996) · PubMed · Cited by 66
Marin, C., Beauchet, A., Capper, D., Zimmermann, U. S., Julié, C., Ilié, M., Saïag, P., von Deimling, A., Hofman, P. M., & Emile, J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0031-oa · Cited by 60
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma
Pearlstein, M. V., Zedek, D. C., Ollila, D. W., Treece, A. L., Gulley, M. L., Groben, P. A., & Thomas, N. E. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12364 · Cited by 59
Detection of BRAF V600 Mutations in Metastatic Melanoma
Qu, K. Z., Pan, Q., Zhang, X., Rodríguez, L. R., Zhang, K., Li, H., Ho, A. K., Sanders, H. R., Sferruzza, A. D., Cheng, S.-M., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.07.003 · Cited by 59
López‐Ríos, F., Angulo, B., Gomez, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053733 · Cited by 56
Bradish, J. R., & Liang Cheng, C. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.001 · Cited by 55
A multi-enzyme model for pyrosequencing
Agah, A., Aghajan, M., Mashayekhi, F., Amini, S., Davis, R. W., Plummer, J. D., Ronaghi, M., & Griffin, P. B. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh159 · Cited by 54
Anwar, M. A. F., Murad, F. G., Dawson, E., Elmageed, Z. Y. A., Tsumagari, K., & Kandil, E. H. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.04.029 · Cited by 54
BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
Chiappetta, C., Proietti, I., Soccodato, V., Puggioni, C., Zaralli, R., Pacini, L., Porta, N., Skroza, N., Petrozza, V., Potenza, C., et al. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000071 · Cited by 53
Chen, G., McQuade, J. L., Panka, D. J., Hudgens, C. W., Amin‐Mansour, A., Mu, X. J., Bahl, S., Jané‐Valbuena, J., Wani, K., Reuben, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0509 · Cited by 46
Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K. L., Sen, J. D., Malek, A. J., Katona, T. M., Warren, S. J. P., Logan, T. F., Fecher, L. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.136 · Cited by 42
Cheng, L., & Zhang, D. Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-405-6 · Cited by 37
Self-citationManfredi, L., Meyer, N., Tournier, É., Grand, D., Uro‐Coste, E., Rochaix, P., Brousset, P., & Lamant, L. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2326 · Cited by 36
BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Eriksson, H., Zebary, A., Vassilaki, I., Omholt, K., Ghaderi, M., & Hansson, J. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.3689 · Cited by 32
Schirosi, L., Strippoli, S., Gaudio, F. D., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2951-4 · Cited by 32
Chen, D., Wang, Y., Chuai, Z.-R., Huang, J.-F., Wang, Y., Liu, K., Zhang, L.-Q., Yang, Z., Shi, D., Liu, Q., et al. (2014) · Scientific Reports · doi:10.1038/srep04168 · Cited by 29
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Su, M. Y., & Fisher, D. E. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002196 · Cited by 23
Liquid Biopsies for Assessing Metastatic Melanoma Progression
Huynh, K. T., & Hoon, D. S. �. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2016016075 · Cited by 19
Bradish, J. R., Montironi, R., Antonio Lopez-beltran, B., Post, K. M., MacLennan, G. T., & Liang Cheng, C. (2013) · Future Oncology · doi:10.2217/fon.12.179 · Cited by 16
Self-citationLong, G. V., Hamid, O., Hodi, F. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps9596 · Cited by 12
Cited by
Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F., & Collins, J. J. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00760-7 · Cited by 1,259
Current approaches to the management of brain metastases
Suh, J. H., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Sahgal, A., & Chang, E. L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0320-3 · Cited by 553
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Systemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 265
Metadata
- Authors
- Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 31
- Issue
- 1
- Pages
- 24-38
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2770795622
- Cited by
- 407
- References
- 88
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.